TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today?
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today?
-
Narrado por:
-
De:
In this episode, Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer, including:
- TROP2-targeting ADCs: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan
- TROP2 ADCS for patients with EGFR-mutated NSCLC
- TIGIT-targeting agents: domvanalimab, rilvegostomig
Presenters:
Benjamin Levy, MD, FASCO
Associate Professor
Johns Hopkins School of Medicine
Clinical Director
Johns Hopkins Kimmel Cancer Center, National Capitol Region (NCR)
Washington, DC
Alex Spira, MD, PhD, FASCO
Director Clinical Research
Virginia Cancer Specialists
CEO NEXT Oncology Virginia
Fairfax, Virginia
Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.
Link to full program:
https://bit.ly/4qZLR6B
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.